Concise Prescribing Info
In conjunction w/ a well-balanced calorie-controlled diet & other appropriate measures (eg, exercise) for the treatment of obese patients w/ a BMI ≥30 kg/m2, or overwt patients w/ BMI ≥28 kg/m2 w/ obesity-related risk factors.
Dosage/Direction for Use
Should be taken with food: Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.
Hypersensitivity. Chronic malabsorption syndrome; cholestasis; certain pancreatic problems; recent major surgery in the stomach or intestines. Pregnancy (not recommended) & lactation. Childn or adolescents <18 yr.
Special Precautions
Patients suffering from chronic malabsorption syndrome; w/ vit deficiencies, kidney stones, peptic ulcer, symptomatic cholelithiasis, post-surgical adhesions, eating disorder, significant heart, kidney, liver GI or endocrine disorders; high cholesterol, diabetes; receiving long-term treatment for mental or nerve disorders; or those taking large doses of laxatives. Allergy to other drugs, foods or dyes. Concomitant use w/ other drugs. May cause changes in the bowel habits eg, fatty or oily stools. Additional contraceptive method is recommended to prevent possible failure of OCs in case of severe diarrhoea. May be associated w/ renal stones in patients suffering from chronic kidney disease.
Adverse Reactions
Headache, abdominal pain/discomfort, urgent or increased need to open the bowels, flatulence w/ discharge, oily discharge, oily or fatty stools, liqd stools, low blood sugar levels. Rectal pain/discomfort, soft stools, incontinence, bloating, tooth/gum disorder, irregularity of menstrual cycle, tiredness.
Drug Interactions
Anticoagulants eg, warfarin (monitor blood coagulation); ciclosporin. Cases of hypothyroidism &/or reduced control of hypothyroidism w/ iodine salts &/or levothyroxine. May affect absorption of some fat soluble nutrients. Decreased absorption of antiepileptics leading to convulsions. Amiodarone, acarbose & other wt loss medicines.
MIMS Class
Anti-Obesity Agents
ATC Classification
A08AB01 - orlistat ; Belongs to the class of peripherally acting antiobesity products.
Xenical cap 120 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in